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Abstract 
Introduction:  Corticosteroid-induced osteonecrosis of the femoral head (ONFH) often affects both femoral heads. 
Such bilateral ONFH cases are generally detected concurrently on magnetic resonance imaging (MRI). On the other 
hand, in unilateral cases, it is rare that contralateral ONFH is subsequently detected. We herein report a case in which 
bilateral ONFH was detected in both femoral heads by repeated MRI examination at an interval of 6 weeks.
Case description: A 34-year-old man with purpura nephritis was started on corticosteroid therapy with predniso-
lone at 30 mg/day. Eight months after the initiation of corticosteroid therapy, he complained of left hip pain with no 
antecedent triggering activity. MRI obtained 8.5 months after the initiation of corticosteroid therapy showed the find-
ings of osteonecrosis of the left femoral head, while no abnormalities were detected in the right femoral head. On the 
second MRI obtained 10 months after the initiation of corticosteroid treatment, however, osteonecrosis of the right 
femoral head was newly detected without an increase of the corticosteroid dose.
Conclusions: This case may indicate that corticosteroid-induced bilateral ONFH do not always develop at the same 
time.
Keywords: Osteonecrosis of the femoral head, Magnetic resonance imaging, Corticosteroid, Bilateral
© 2015 Sonoda et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Nontraumatic osteonecrosis of the femoral head (ONFH) 
is considered to be the result of an ischemic event, lead-
ing to the death of osteocytes. Although several possible 
factors—hyperlipidemia, coagulation abnormalities, oxi-
dative stress—have been suggested as the pathogenesis of 
ONFH, the precise mechanism remains unclear (Moto-
mura et  al. 2008; Nishida et  al. 2008; Shuai et  al. 2010; 
Ichiseki et  al. 2011). Corticosteroid use is considered 
to be one of the major causative factors, and especially, 
high-dose corticosteroid therapy has been suggested as 
an important factor in the development of ONFH (Mont 
et  al. 1997; Oinuma et  al. 2001; Fukushima et  al. 2010; 
Nakamura et al. 2010).
Corticosteroid-induced ONFH has been reported to 
develop early (1–2 months) after starting high-dose cor-
ticosteroid therapy, and the probability of affecting both 
femoral heads is considered to be approximately 80  % 
(Shigemura et  al. 2012). In these bilateral cases, ONFH 
can be detected on magnetic resonance imaging (MRI) 
concurrently in the majority of cases (Oinuma et al. 2001; 
Fukushima et  al. 2010). On the other hand, in patients 
with unilateral ONFH, it is rare that ONFH subsequently 
occurs on the contralateral side unless the corticosteroid 
dose had been increased. There is only one case report 
in which contralateral ONFH was detected at an inter-
vals of 8 days, in which both ONFH were detected within 
5  weeks after the initiation of corticosteroid therapy 
(Zhao et al. 2015).
We present a rare case in which ONFH was detected 
in both femoral heads at an interval of 6 weeks on MRI 
which were performed 8.5 and 10  months after the 
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initiation of corticosteroid therapy. Written informed 
consent for publication of the case was obtained from the 
patient.
Case description
A 34-year-old man (height 172  cm, weight 87  kg, body 
mass index 29.4  kg/m2) had been followed for purpura 
nephritis since he was 18 years of age. Since 32 years of 
age, he had been treated for hyperlipidemia with 20 mg 
of atorvastatin (cholesterol-lower agent). He had no his-
tory of alcohol abuse or smoking. Because of the gradual 
progression of renal failure, he was started on corticos-
teroid therapy (prednisolone at 30  mg/day) for the first 
time at 34 years of age.
The time course of the corticosteroid therapy is shown 
in Fig. 1. Two months after the initiation of corticosteroid 
therapy, he underwent tonsillectomy followed by corti-
costeroid pulsed treatment (500  mg of methylpredniso-
lone for 6 days) for purpura nephritis. The prednisolone 
dose was gradually decreased, declining to 10 mg/day at 
6  months after its initiation. He was not on any diet or 
exercise program during the corticosteroid therapy, even 
though he was overweight.
Eight months after the initiation of corticosteroid ther-
apy, he complained of left hip pain with no antecedent 
triggering activity. T1-weighted MRI scans obtained 
2  weeks after the onset demonstrated a low-intensity 
band lesion in the left femoral head (Fig. 2). On the other 
hand, there was no obvious abnormality in the right fem-
oral head. On short tau inversion recovery (STIR) images, 
an associated bone marrow edematous lesion was con-
firmed distal to the band lesion on the left side, indicat-
ing the occurrence of femoral head collapse (Fig. 3). The 
patient was diagnosed with unilateral osteonecrosis of 
the left femoral head and was referred to our department.
Although osteonecrosis of the left femoral head had 
collapsed already, joint preserving procedures, such as 
osteotomy and bone grafting, were considered to be 
more suitable than total hip arthroplasty since the patient 
was relatively young. For the purpose of evaluating the 
indications of osteotomy, he underwent MRI again 
6  weeks after the initial MRI. This time, a low-inten-
sity band newly appeared in the right femoral head on 
T1-weighted images (Fig. 4). STIR images did not reveal 
a bone marrow edema (Fig.  5). The second MRI scans 
demonstrated the new development of osteonecrosis in 
the right femoral head. As the right hip was asympto-
matic and the patient did not will additional treatments, 
we decided to observe conservatively without restricting 
weight-bearing unless the right hip became symptomatic. 
Fig. 1 Time course for the prednisolone doses and the serum lipid levels. A 34-year-old man with purpura nephritis was started on corticosteroid 
therapy with prednisolone. Time course for the prednisolone doses and the serum lipid levels: triglycerides (TG), total cholesterol (TC), low-density 
lipoprotein cholesterol (LDL), and high-density lipoprotein cholesterol (HDL). * Corticosteroid pulsed treatment: methylprednisolone 500 mg/
day × 6 days
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Thereafter, his left hip underwent transtrochanteric ante-
rior rotational osteotomy. Postoperatively, the patients 
started to perform active range of motion exercise 5 days 
after the operation and began to use wheelchairs at the 
same time. His left hip was maintained non-weight-bear-
ing status until 5  week after the operation, followed by 
partial weight-bearing walking using two crutches. Full 
weight-bearing walking was permitted 4 months after the 
operation. His right hip had remained asymptomatic as 
of 8 months after the second MRI scans (7.8 months after 
the operation). At that time, the low intensity band was 
observed more obviously on T1-weighted images. 
The time courses of the patient’s serum lipid levels 
(triglycerides, total cholesterol, low-density lipoprotein 
cholesterol, high-density lipoprotein cholesterol) are 
shown in Fig. 1. The serum level of triglycerides showed 
transient elevation twice during the period of observa-
tion (2.5 and 8.5 months after the initiation of corticos-
teroid therapy). The first elevation occurred immediately 
after corticosteroid pulse treatment, while the second 
occurred without obvious trigger events including the 
increase in the dose of corticosteroids. No other param-
eters showed significant elevations during the period of 
observation. There were also no remarkable changes in 
his coagulation parameters, hepatic enzymes, or C-reac-
tive protein level.
Discussion and evaluation
Oinuma et  al. reported that corticosteroid-induced 
ONFH develops very early (1–2  months) after start-
ing high-dose corticosteroid therapy, which could be 
detected at least 3  months after the initiation of treat-
ment in all the cases (Oinuma et  al. 2001). In the cur-
rent case, it is considered that osteonecrosis of the left 
femoral head had developed early after either high-dose 
oral corticosteroid therapy (30  mg/day) or the corticos-
teroid pulsed treatment. In the right side, however, no 
evidence of osteonecrosis could be detected on the first 
MRI obtained 6 months after corticosteroid pulse treat-
ment, indicating the difference in timing of the develop-
ing osteonecrosis.
It is rare that contralateral ONFH newly develops in 
unilateral cases. To our knowledge, there are two case 
reports presenting new corticosteroid-induced ONFH 
developing in the contralateral femoral head. In one 
case, the corticosteroid dose had been increased to more 
than 30  mg/day before ONFH developed in the con-
tralateral hip (Sonoda et al. 2015). In another case, new 
Fig. 2 A coronal T1-weighted magnetic resonance image obtained 
8.5 months after the initiation of corticosteroid therapy for purpura 
nephritis. Note the low-intensity band lesion in the left femoral head 
but no obvious abnormality in the right femoral head
Fig. 3 A coronal short-tau inversion recovery (STIR) image obtained 
8.5 months after the initiation of corticosteroid therapy. Note the 
bone marrow edematous lesion distal to the band lesion on the left 
side, indicating femoral head collapse
Fig. 4 A coronal T1-weighted image obtained 10 months after the 
initiation of corticosteroid therapy (6 weeks after the first examina-
tion). Note the new T1 low-intensity band in the right femoral head
Fig. 5 A coronal STIR image obtained 10 months after the initiation 
of corticosteroid therapy (6 weeks after the first examination). Edema-
tous changes were not seen in the right femoral head
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contralateral ONFH was detected on MRI at an interval 
of 8 days within 5 weeks after the initiation of corticos-
teroid therapy, indicating that new contralateral ONFH 
developed immediately after the initiation of corticos-
teroid treatment (Zhao et  al. 2015). In contrast, in the 
current case, the first MRI presenting no evidence of 
osteonecrosis in the contralateral hip was performed at 
8.5  months after the initiation of corticosteroid therapy 
(6 months after the corticosteroid pulse treatment).
It remains unclear why new ONFH developed in the 
current case, however, one possible explanation may 
be the hyperlipidemia. The serum level of cholesterol 
showed no remarkable changes while that of triglycerides 
had elevated twice after the initiation of corticosteroid 
therapy; the first elevation occurred immediately after 
corticosteroid pulse treatment, and the second occurred 
8.5 months after the initiation of corticosteroid therapy. 
A previous study suggested that hypertriglyceridemia was 
associated with the development of ONFH (Bhojwani 
et  al. 2014). In animal models of corticosteroid-induced 
osteonecrosis, corticosteroid-induced hypertriglyceri-
demia was suggested to be associated with the develop-
ment of osteonecrosis (Yamamoto et  al. 1997; Kabata 
et al. 2005; Motomura et al. 2008; Pengde et al. 2008). In 
the current case, the second elevation of serum level of 
triglycerides may thus be associated with the develop-
ment of contralateral ONFH. The patient had received 
a cholesterol-lower agent, however, a triglyceride-lower 
agent had never been prescribed.
Conclusions
Bilateral ONFH generally develops simultaneously after 
the initiation of corticosteroid therapy. Considering the 
current case, however, it should be noted that corticos-
teroid-induced bilateral ONFH do not always developed 
at the same time.
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